MONTREAL--(BUSINESS WIRE)--Nov. 14, 2005--MethylGene Inc. (TSX:MYG) a biopharmaceutical company, today announced that it has initiated the first of several Phase I/II clinical trials which will evaluate the combination therapy using MGCD0103 and azacitidine (Vidaza(TM), Pharmion Corporation) in patients with advanced myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML).
